TCL-1B3 Inhibitors
Chemical inhibitors of TCL-1B3 can disrupt various signaling pathways within cells by targeting specific proteins that TCL-1B3 relies on for its functions. Staurosporine, for instance, targets protein kinase C, whose inhibition can prevent the phosphorylation events that TCL-1B3 depends on, thereby directly affecting its activity. Similarly, the chemicals Wortmannin and LY294002 both act on phosphoinositide 3-kinases (PI3K), crucial components in TCL-1B3's signaling pathways. By inhibiting PI3K, these compounds can disrupt the signaling, leading to an inhibition of TCL-1B3's cellular activities. Rapamycin, by binding to FKBP12, inhibits mTOR, another key protein in the pathways associated with TCL-1B3. The inhibition of mTOR by Rapamycin can cut off downstream signaling required for TCL-1B3's activity.
In addition to these, U0126 and PD98059 target MEK1/2, which are upstream regulators of the ERK pathway, a key pathway in which TCL-1B3 is involved. By blocking MEK1/2, these inhibitors can prevent the activation of ERK, further inhibiting the signaling processes necessary for TCL-1B3's functionality. Meanwhile, SP600125 and SB203580 focus on inhibiting the c-Jun N-terminal kinase (JNK) and p38 MAP kinase, respectively, both of which are associated with signaling pathways that encompass TCL-1B3. Inhibition of these kinases by SP600125 and SB203580 can lead to the suppression of essential signaling events for the function of TCL-1B3. Src family kinases, implicated in TCL-1B3-related pathways, can be inhibited by PP2 and Dasatinib, which disrupts the signaling necessary for TCL-1B3's proper functioning. Lastly, Gefitinib and Erlotinib inhibit the epidermal growth factor receptor (EGFR) tyrosine kinase, which is also associated with TCL-1B3 signaling pathways. By inhibiting EGFR, Gefitinib and Erlotinib can lead to a disruption of the pathways, effectively inhibiting the function of TCL-1B3.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits protein kinase C, which is involved in the signaling pathways that TCL-1B3 participates in. By inhibiting this kinase, Staurosporine prevents the phosphorylation events required for TCL-1B3 to exert its cellular functions, resulting in the functional inhibition of TCL-1B3. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which play a role in the signaling pathways utilized by TCL-1B3. Inhibition of PI3K leads to a disruption of these pathways, thereby inhibiting the cellular activities in which TCL-1B3 is involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 specifically inhibits phosphoinositide 3-kinases (PI3K), which are crucial for the signaling cascades that involve TCL-1B3. By blocking PI3K, LY294002 disrupts the pathway, effectively inhibiting the function of TCL-1B3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR, which is a component of the signaling pathways that TCL-1B3 is part of. The inhibition of mTOR prevents the downstream signaling required for TCL-1B3's activity, thereby functionally inhibiting TCL-1B3. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of the ERK pathway, a pathway in which TCL-1B3 is involved. By inhibiting MEK1/2, U0126 blocks the activation of ERK, thereby inhibiting the signaling processes necessary for TCL-1B3 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is associated with signaling pathways that include TCL-1B3. Inhibition of JNK by SP600125 leads to the suppression of signaling events that are essential for the functionality of TCL-1B3. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is implicated in pathways involving TCL-1B3. By blocking p38 MAP kinase activity, SB203580 disrupts the signaling required for TCL-1B3's role in cellular functions, thus inhibiting TCL-1B3. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is upstream of the ERK pathway, a key pathway for TCL-1B3 function. The inhibition of MEK by PD98059 results in the blockade of ERK pathway signaling, leading to the functional inhibition of TCL-1B3. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of the Src family of tyrosine kinases, which are involved in the signaling pathways connected with TCL-1B3. By inhibiting these tyrosine kinases, PP2 disrupts the signaling necessary for the proper functioning of TCL-1B3, thereby inhibiting it. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that targets Src family kinases which are a component of the cellular pathways involving TCL-1B3. Through its inhibitory action, Dasatinib disrupts the signaling cascade necessary for TCL-1B3 function, resulting in its inhibition. | ||||||